Meta-analysis identifies risk factors for venous thromboembolism in patients with lymphoma. A meta-analysis identified multiple factors associated with venous thromboembolism in patients with lymphoma.
Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma.
Researchers determined midostaurin in combination with intensive chemotherapy is well tolerated with high response rates in fit adult patients with FLT3-mutated AML.
The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.